The protein-based vaccine, after two Phase III clinical trials involving over 3,000 participants, was found to be safe, at least 90% effective in preventing symptomatic cases of the original coronavirus strain, and at least 80% effective in preventing symptomatic cases of the delta variant.
The vaccine will be deployed in other underserved countries following India, according to a news release.
